SAR of 3,4-Dihydropyrido[3,2-d]pyrimidone p38 inhibitors
摘要:
Development for a class of potent 3,4-dihydropyrido(3,2-d)pyrimidone inhibitors of p38a MAP kinase is described. Modification of N-1 aryl and C-6 arylsulfide in 3,4-dihydropyrido (3,2-d)pyrimidone analogues for the interaction with the hydrophobic pockets in p38 active site is also discussed. (C) 2003 Elsevier Ltd. All rights reserved.
[EN] BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES ET LEURS UTILISATIONS THÉRAPEUTIQUES
申请人:ASTEX THERAPEUTICS LTD
公开号:WO2012143725A1
公开(公告)日:2012-10-26
The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2, R3, A, W, U and V are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY
申请人:Buck Ildiko Maria
公开号:US20140045831A1
公开(公告)日:2014-02-13
The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R
1
, R
2
, R
3
, A, W, U and V are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
Bicyclic heterocycle compounds and their uses in therapy
申请人:Buck Ildiko Maria
公开号:US09155743B2
公开(公告)日:2015-10-13
The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2, R3, A, W, U and V are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.